SCHEMBL3262344

SCHEMBL3262344

C=C(C)c1cc2ncc(C(=O)OCC)c(N)n2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.61
RAB9A P51151 6/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
KMT2A Q03164 6/20 0.59
MAPT P10636 5/20 0.59
MEN1 O00255 5/20 0.59
CYP2C19 P33261 3/20 0.59
GAA P10253 3/20 0.59
CYP2C9 P11712 2/20 0.59
ALDH1A1 P00352 5/20 0.56
KDM4E B2RXH2 9/20 0.54
TSHR P16473 2/20 0.49
POLB P06746 1/20 0.48
HTT P42858 1/20 0.48
RECQL P46063 1/20 0.48
HPGD P15428 4/20 0.47
TP53 P04637 2/20 0.47
NFKB1 P19838 1/20 0.47
STAT1 P42224 1/20 0.47
NFKB2 Q00653 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10286758 0.86 NPC1 (0.45) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL235867 0.82 RAB9A (0.69) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL238576 0.81 NPC1 (0.62) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL238840 0.81 NPC1 (0.64) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL239039 0.78 NPC1 (0.63) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL2755213 0.78 RAB9A (0.83) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL236799 0.77 NPC1 (0.68) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL238859 0.77 NPC1 (0.78) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL235812 0.76 NPC1 (0.80) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL236798 0.76 NPC1 (0.61) NPC1RAB9ASMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.